News Novartis' Mayzent EU approval offers SPMS patients new optio... Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.
News Novartis sets up free lottery for $2.1m SMA drug outside US Novartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma in countries outside the US where it is not yet approved, in a controversi
Views & Analysis 2019: the year of the pharma mega-merger 2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
